Effect of P-Glycoprotein Inhibitor Verapamil on Pharmacokinetics of Loureirin A B C in Rats

被引：0

作者：

Li Y.-J. ^{[1
]}

Kang L.-T. ^{[1
]}

Guo J.-J. ^{[1
]}

Wang S.-B. ^{[1
]}

Li Y.-Z. ^{[2
]}

Wang J.-P. ^{[2
]}

Gao J.-Y. ^{[2
]}

机构：

[1] School of Life Science, Beijing Institute of Technology, Beijing

[2] China Astronaut Research and Training Centre, Beijing

来源：

Li, Yu-Juan (lylyjlzh2006@163.com) | 1600年 / Beijing Institute of Technology卷 / 40期

关键词：

Dragon's Blood; P-glycoprotein; Pharmacokinetic; Verapamil;

D O I：

10.15918/j.tbit1001-0645.2018.289

中图分类号：

学科分类号：

摘要：

To study how P-glycoprotein inhibitor verapamil affect pharmacokinetics of the active constituents Loureirin A, B and C in rat plasma after oral administration of Dragon's Blood, SD rats were randomly put into different group: control group and inhibitor group. A single dose of 5 g/kg of Dragon's Blood was orally administered to rats in control group, and rats in the inhibitor group were given verapamil (1 mg/kg) and Dragon'Blood (5 g/kg). Plasma samples were collected from the two groups in the same series of time. A HPLC-MS/MS method was used to determine the content of Loureirin A, B and C in rat plasma, and the plasma samples pharmacokinetic parameters were calculated. Comparing the area under curve (AUC0-t) of the rats in the inhibitor group with the control group, it increased by 109.4%, 78.5%, 22.8%. And the peak concentration(Cmax) of Loureirin A, B and C increased by 69.6%, 115.0%, and 42.1%. The time of Loureirin A and B reaching peak concentration (tmax) was prolonged, while the tmax of Loureirin C was unchanged. All three biological half-life (t0.5) decreased. It indicates that P-glycoprotein inhibitor can significantly change the plasma pharmacokinetic parameters of Loureirin A, B and C in rats. Loureirin A, B and C may be potential substrates of P-glycoprotein. This article provides basic data for the subsequent in-depth study of the relationship between P-glycoprotein and transportation of Dragon's Blood in the intestinal tract of rats. © 2020, Editorial Department of Transaction of Beijing Institute of Technology. All right reserved.

引用

页码：105 / 110

页数：5

共 23 条

[21]

Chen X., Ma Y., Zhong J., Research progress of bimodal phenomenon in drug concentration-time curve, Chinese Journal of New Drugs and Clinical Remedies, 8, pp. 432-437, (2012)

[22]

Davies D.N.M., Takemoto J.K., Brocks D.R., Et al., Multiple peaking phenomena in pharmacokinetic disposition, Clinical Pharmacokinetics, 49, 6, pp. 351-377, (2010)

[23]

Li X., Establishment and application of human P-glycoprotein high expression MDR1-MDCKⅡ cell model. and preclinical pharmacokinetic study of a novel lipid-regulating compound IMM-H007, (2014)

← 1 2 3 →